Literature DB >> 1754068

Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies.

M L Simmons1, C G Frondoza, J T Coyle.   

Abstract

N-Acetyl-aspartate is found in high concentrations in all areas of the brain, but is undetectable in non-neuronal tissue. In order to characterize the cellular localization of N-acetyl-aspartate in brain, highly specific monoclonal antibodies against N-acetyl-aspartate were produced by fusing spleen lymphocytes obtained from mice immunized with N-acetyl-aspartate conjugated to thyroglobulin by carbodiimide with P3/x63-Ag8.653 mouse myeloma cells. Clones were selected which secrete IgG2a(k) antibodies highly specific for conjugated N-acetyl-aspartate. Only 3-6% cross-reactivity with conjugated N-acetyl-aspartate-glutamate was observed at high antibody concentrations, whereas no cross-reactivity (less than 1%) was observed with conjugated N-acetyl-glutamate or aspartate. Preincubation of the antibodies with 0.5 mg/ml conjugated N-acetyl-aspartate blocked immunoreactivity more than 90%, while preincubation with conjugated N-acetyl-aspartate-glutamate and free N-acetyl-aspartate had no effect. Immunocytochemical staining has shown that N-acetyl-aspartate-like immunoreactivity is localized in neurons, which are widely distributed throughout the brain. The immunoreactive neurons exhibited intense staining of the perikarya, proximal dendrites and axons. No consistent pattern of distribution of immunoreactivity was observed with regard to primary neurotransmitter characteristics of stained neurons although neurons with long projections or extensive arbors, such as pyramidal cells in cortex, locus coeruleus, motor neurons and Purkinje cells, stained much more intensively than local circuit neurons.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1754068     DOI: 10.1016/0306-4522(91)90101-s

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  128 in total

Review 1.  Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer.

Authors:  J Kurhanewicz; D B Vigneron; S J Nelson
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  MR spectroscopy and spectroscopic imaging of the brain.

Authors:  He Zhu; Peter B Barker
Journal:  Methods Mol Biol       Date:  2011

3.  Longitudinal whole-brain N-acetylaspartate concentration in healthy adults.

Authors:  D J Rigotti; I I Kirov; B Djavadi; N Perry; J S Babb; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2011-04-21       Impact factor: 3.825

4.  [MR spectroscopy in dementia].

Authors:  T Hauser; L Gerigk; F Giesel; L Schuster; M Essig
Journal:  Radiologe       Date:  2010-09       Impact factor: 0.635

5.  Whole-brain N-acetylaspartate spectroscopy and diffusion tensor imaging in patients with newly diagnosed gliomas: a preliminary study.

Authors:  M Inglese; S Brown; G Johnson; M Law; E Knopp; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

6.  Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression.

Authors:  Talaignair N Venkatraman; Ranga R Krishnan; David C Steffens; Allen W Song; Warren D Taylor
Journal:  Psychiatry Res       Date:  2009-04-30       Impact factor: 3.222

7.  Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS.

Authors:  Charlotte J Stagg; Steven Knight; Kevin Talbot; Mark Jenkinson; Andrew A Maudsley; Martin R Turner
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

8.  Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis.

Authors:  Mike P Wattjes; Michael Harzheim; Götz G Lutterbey; Manuela Bogdanow; Stephan Schmidt; Hans H Schild; Frank Träber
Journal:  Neuroradiology       Date:  2007-11-03       Impact factor: 2.804

9.  Axonal degeneration and progressive neurologic disability in multiple sclerosis.

Authors:  Carl Bjartmar; Bruce D Trapp
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.